1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsOther Transaction Agreements (OTAs) is sponsored by BARDA. Flexible, strategic partnerships between the government and industry to foster innovation and promote collaboration in medical countermeasure development.
Get alerted about grants like this
Save a search for “BARDA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Medical Countermeasures | Accelerated Preparedness Partnerships only on official, secure websites PREPAREDNESS PARTNERSHIPS Other Transaction Agreements and the Consortium-based Acquisition Model New partnership models to enhance collaboration, accelerate MCM development, and expand domestic manufacturing Unlocking Innovation: The Strategic Use of Other Transaction Agreements (OTAs) and the Consortium Model The Government employs OTAs to advance research and development, foster innovation, and support public health initiatives.
These agreements form flexible partnerships between the government and industry, encourage open communication, expedite technology acquisition, and engage a diverse range of developers, manufacturers, and suppliers including those that are not accustomed to the government acquisition process.
Government procurement and the innovative solutions it seeks are often complex and multifaceted and require diverse skills, resources, and expertise that may be best attained through a team of performers. Enter the consortium model where a consortium brings together traditional and non-traditional industry partners, non-profit organizations, and academia aligned to a specialized technical area.
Coupled with the flexibility of OTAs, the OTA consortium model further promotes collaboration, facilitates adoption of efficient business practices that can dramatically improve speed of acquisitions when needed (e.g., during a public health emergency), and provides the Government with greater visibility and access to performers with specialized abilities to create the most impactful solutions.
Rapid Response Partnership Vehicle (RRPV) The Rapid Response Partnership Vehicle (RRPV) supports the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the advanced development of Medical Countermeasure (MCM) products and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.
It is comprised of a collaborative, agile network of technologists, innovators, traditional contractors, large and small business, academia, and nonprofit research institutions that can respond rapidly and effectively to future pandemic or high consequence biological threats.
The consortium brings together members focused on Medical Technology (MedTech) including diagnostics, Vaccines (Vx), and Therapeutics (Tx) to accelerate partnering, improve responsiveness, and meet expanding demand to develop future MCM solutions. It will also ensure that, during a response event, sufficient dedicated resources are available to meet bold timelines and avoid one focus area diverting resources from the other.
These solutions will range from early-stage development through advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The consortium will advance health security, enhance preparedness, and enable a rapid response to the next pandemic or public health emergency.
Developing a robust network to advance mission-relevant technologies Advancing Health Security Facilitating research and development of medical countermeasures Preparedness and Response Dynamic and rapid response to emerging situations Select a domain to learn more or visit the RRPV website to learn more. Medical Technology (MedTech) MedTech refers to tools, equipment, and devices to diagnose and treat patients.
Vx refers to a biological preparation used to stimulate the body's immune response against viruses or diseases. Tx refers to medical intervention intended to treat a health issue, viruses, or disease.
Review our active solicitations The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports the Biomedical Advanced Research and Development Authority (BARDA) and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services.
This consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation’s public health preparedness and response requirements.
Fast and flexible partnership mechanism for executing biopharmaceutical manufacturing requirements Select a domain to learn more or visit the BioMaP Consortium website to learn more.
Industrial Base Expansion (IBx) Engaging providers of goods and services that support the entire biomanufacturing process to strengthen the domestic supply chain (raw materials, consumables, etc.) Capacity Expansion and Reservation Establishing, expanding, and reserving drug substance and drug product to prepare timely and sufficient MCMs in response to emerging pathogens with pandemic potential.
Advanced Biomanufacturing Technologies Technologies that are: new, emerging, and innovative; enhance existing technologies; and/or increase the speed, quality, safety, yield, and efficiency of the biomanufacturing process.
Review our active solicitations Additonal Opportunities to partner with barda BARDA’s Broad Agency Announcement (BAA) solicits proposals for the advanced research and development of medical countermeasures (MCMs) such as vaccines, therapeutics, diagnostics, and devices.
The BAA is intended for advanced research and development of MCMs to counter chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases. The BAA is for projects aligned with open Areas of Interest (AOIs) specific to the solicitation.
The Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) and seeks abstracts for efforts to develop revolutionary health security products, technologies, and innovations in order to increase the Government’s capability and capacity to respond to national security health threats.
The USG seeks information from stakeholders on available medical countermeasures in development. BARDA is particularly interested in products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform.
Based on current listing details, eligibility includes: Nonprofits, Universities, State/local governments, Small businesses, For-profit organizations Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.